8-K: 89bio Progresses MASH, SHTG Trials; Q2 Net Loss Widens

89bio, Inc. announced Q2 2025 financial results and provided updates on its Phase 3 trials for pegozafermin in MASH and SHTG, with key data expected in 2026-2028.

Summary

• Reported second quarter 2025 financial results and provided corporate updates.
• Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic MASH (F2-F3) expects topline histology data in the first half of 2027.
• Phase 3 ENLIGHTEN-Cirrhosis trial in compensated cirrhotic MASH (F4) expects topline histology data in 2028.
• Both MASH trials are designed to support accelerated approval based on alignment with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).
• Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) expects topline data in the first quarter of 2026.
• Cash, cash equivalents, and marketable securities totaled $561.2 million as of June 30, 2025.
• Net loss for the second quarter of 2025 was $111.5 million, compared to $48.0 million for the same period in 2024.
• Research and Development (R&D) expenses increased to $103.9 million in Q2 2025 from $44.9 million in Q2 2024, primarily due to Phase 3 MASH trials and a $42.4 million non-recurring payment for a commercial-scale production facility.

Sentiment

Score: 6

Explanation: The company is making solid clinical progress with its lead candidate, pegozafermin, in two significant indications (MASH and SHTG), with clear timelines for Phase 3 data and an accelerated approval pathway. The cash position is strong. However, the net loss and R&D expenses have significantly increased, reflecting the high cost of late-stage clinical development, which is typical for a biopharmaceutical company at this stage.

Positives

• Maintained a strong cash position of $561.2 million as of June 30, 2025, an increase from $439.955 million at December 31, 2024.
• Continued enrollment and progress across three global Phase 3 trials for pegozafermin in MASH and SHTG.
• Achieved alignment with the FDA and EMA for accelerated approval pathways for pegozafermin in both non-cirrhotic (F2-F3) and compensated cirrhotic (F4) MASH.
• The commercial-scale production facility for pegozafermin remains on schedule to support the Biologics License Application (BLA) filing.
• Management believes pegozafermin is poised to potentially deliver best-in-class relative risk ratio on histology endpoints, a favorable safety and tolerability profile, and a convenient dosing approach.

Negatives

• Net loss significantly increased to $111.5 million for the second quarter of 2025, compared to $48.0 million for the second quarter of 2024.
• Research and Development (R&D) expenses more than doubled to $103.9 million for Q2 2025, up from $44.9 million for Q2 2024, driven by trial costs and a non-recurring facility payment.
• General and Administrative (G&A) expenses increased to $11.9 million for Q2 2025 from $8.6 million for Q2 2024, primarily due to higher personnel-related expenses and headcount.

Risks

• Expectations regarding the timing and outcome of the ENLIGHTEN-Fibrosis Phase 3 trial, Phase 3 ENLIGHTEN-Cirrhosis trial in MASH, and ENTRUST Phase 3 trial in SHTG.
• Ability to execute on its strategy.
• Positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies.
• Substantial dependence on the success of its lead product candidate, pegozafermin.
• Competition from competing products.
• Impact of general economic, health, industrial, or political conditions in the United States or internationally, including recently announced tariffs and potential additional tariffs.
• FDA and comparable foreign regulatory authorities changing leadership or policies, or issuing additional regulations or revising existing regulations.
• Sufficiency of capital resources and ability to raise additional capital.

Future Outlook

The company anticipates topline data from the Phase 3 ENTRUST trial in SHTG in the first quarter of 2026. For MASH, topline histology data from ENLIGHTEN-Fibrosis is expected in the first half of 2027, and from ENLIGHTEN-Cirrhosis in 2028, with these data intended to support accelerated approval filings. The commercial-scale production facility for pegozafermin is on schedule to support the Biologics License Application (BLA) filing, with a final $13.5 million milestone payment due in 2026.

Management Comments

• "As we enter the second half of 2025, we remain diligently focused on execution across our three global Phase 3 trials for pegozafermin in MASH and SHTG."
• "In SHTG, we continue to expect topline data from our Phase 3 ENTRUST trial in the first quarter of 2026."
• "In MASH, we expect topline histology data from ENLIGHTEN-Fibrosis in the first half of 2027, and ENLIGHTEN-Cirrhosis in 2028, underpinning our accelerated-approval filings for patients with F2-F3 and F4 MASH, respectively."
• "As our clinical development program in MASH continues to progress, we believe pegozafermin is poised to potentially deliver best-in-class relative risk ratio on histology endpoints, a favorable safety and tolerability profile, and a convenient dosing approach to the large and underserved MASH patient population."

Industry Context

89bio operates in the highly competitive and rapidly evolving biopharmaceutical sector, specifically targeting liver and cardiometabolic diseases like MASH and SHTG, which represent significant unmet medical needs. Pegozafermin, an FGF21 analog, is positioned against other therapies in development for MASH, where several companies are vying for accelerated approval based on histology endpoints. The company's focus on a potentially 'best-in-class' profile and convenient dosing aims to differentiate it in a crowded market, while its progress in SHTG addresses another critical cardiometabolic condition.

Stakeholder Impact

• Shareholders: Potential for significant value creation if pegozafermin successfully completes trials and gains accelerated approval, but also faces substantial clinical development risks and increased cash burn.
• Patients (MASH & SHTG): Continued hope for a new, potentially best-in-class treatment option for underserved liver and cardiometabolic diseases.
• Employees: Increased headcount and personnel-related expenses suggest growth and stability in employment, particularly in R&D.
• Suppliers/Contract Manufacturers: Increased R&D expenses indicate significant engagement with contract research organizations and manufacturers for clinical trials and drug production.

Next Steps

• Continue enrollment in Phase 3 ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis trials for MASH.
• Generate topline data from Phase 3 ENTRUST trial in SHTG in 1Q 2026.
• Generate topline histology data from Phase 3 ENLIGHTEN-Fibrosis trial in 1H 2027.
• Generate topline histology data from Phase 3 ENLIGHTEN-Cirrhosis trial in 2028.
• Pursue accelerated approval filings for pegozafermin in MASH based on histology data.
• Continue MASH trials for outcomes data to support full approval.
• Complete construction of the commercial-scale production facility for pegozafermin, with a final $13.5 million milestone payment in 2026.

Key Dates

Recommendation

The company is executing well on its clinical development strategy for pegozafermin, with clear timelines for Phase 3 data readouts and a strong cash position to fund operations into these milestones. The alignment with regulatory bodies for accelerated approval in MASH is a significant positive. However, the substantial increase in net loss and R&D expenses reflects the high burn rate typical of a late-stage clinical biopharma, which introduces financial risk. While the long-term potential is considerable, the stock is likely to remain volatile based on clinical trial news and funding needs. A 'hold' recommendation is appropriate for investors awaiting further de-risking through upcoming data readouts, balancing the promising clinical progress against the increased financial expenditures and inherent risks of drug development.

Keywords

89bio, ETNB, Pegozafermin, MASH, NASH, SHTG, Metabolic Dysfunction-Associated Steatohepatitis, Severe Hypertriglyceridemia, Clinical Trials, Phase 3, Biopharmaceutical, Liver Disease, Cardiometabolic Disease, FGF21 analog, Accelerated Approval, FDA, EMA